Article Details

C4 Therapeutics Aims to Launch EGFR L858R Degrader Into the Clinic in 2022

Retrieved on: 2021-05-26 17:26:15

Tags for this article:

Click the tags to see associated articles and topics

C4 Therapeutics Aims to Launch EGFR L858R Degrader Into the Clinic in 2022. View article details on hiswai:

Excerpt

Roche, which transformed an ongoing research and development collaboration with C4 Therapeutics back in 2019, is named a partner involved in the ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up